Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-04-04

Clinical Trial Update: Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting results for ziv-aflibercept in patients with metastatic or unresectable kidney cancer; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ziv-aflibercept (ziv-aflibercept)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-04